Single versus double autologous stem cell transplantation and lenalidomide maintenance versus no maintenance therapy in newly-diagnosed patients with multiple myeloma: a real-life, vintage snapshot after twenty-three years from the Rete Ematologica Pugliese
Analysis reveals how double autologous stem cell transplantation and lenalidomide maintenance impact outcomes in newly diagnosed multiple myeloma patients.
Key Points
Patients receiving double autologous stem cell transplantation had a longer median progression-free survival of 66 months compared to 53 months for single transplantation.
Those who received lenalidomide maintenance therapy enjoyed a median overall survival of 142 months, which is significantly better than the 108-month survival of those who did not.
Factors such as complete remission after first autologous stem cell transplantation and lenalidomide maintenance were key in influencing progression-free survival outcomes.
The findings serve as a historical benchmark in the context of evolving treatments for multiple myeloma patients.